Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice

American Journal of Pathology

Volumn 177, Issue 4, 2010, Pages 2055-2066

  Singh, Shalini ^a,f   Vinson, Charles ^b   Gurley, Cathy M ^a   Nolen, Greg T ^a   Beggs, Marjorie L ^a,g   Nagarajan, Radhakrishnan ^a,h   Wagner, Erwin F ^c   Parham, David M ^d   Peterson, Charlotte A ^e  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; SECRETED FRIZZLED RELATED PROTEIN 2; SURVIVIN; TRANSCRIPTION FACTOR AP 1; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MEMBRANE RESISTANCE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EMBRYONAL RHABDOMYOSARCOMA; GENE CONTROL; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; MYOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C FOS; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 77957357005     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091195     Document Type: Article

References (65)

1. Parham DM, Ellison DA: Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 2006, 130:1454-1465
2. Meyer WH, Spunt SL: Soft tissue sarcomas of childhood. Cancer Treat Rev 2004, 30:269-280
3. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, Triche TJ: Molecular classification of rhabdomyosarcoma: genotypic and phenotypic determinants of diagnosis; a report from the Children's Oncology Group. Am J Pathol 2009, 174:550-564
4. Xia SJ, Pressey JG, Barr FG: Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002, 1:97-104
5. Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, Wan X, Baker KS, Sorensen P, Barr FG: Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer 2002, 33:310-321
6. Zhan S, Shapiro DN, Helman LJ: Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994, 94:445-448
7. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR: Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004, 18:2614-2626
8. Linardic CM, Naini S, Herndon JE, 2nd, Kesserwan C, Qualman SJ, Counter CM: The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res 2007, 67:6691-6699
9. Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM: Genetic modeling of human rhabdomyosarcoma. Cancer Res 2005, 65:4490-4495
10. Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A: Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 1998, 4:619-622
11. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997, 94:701-706
12. Harvey M, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A, Donehower LA: Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 1993, 5:225-229
13. Teitz T, Chang JC, Kitamura M, Yen TS, Kan YW: Rhabdomyosarcoma arising in transgenic mice harboring the beta-globin locus control region fused with simian virus 40 large T antigen gene. Proc Natl Acad Sci USA 1993, 90:2910-2914
14. Fleischmann A, Jochum W, Eferl R, Witowsky J, Wagner EF: Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell 2003, 4:477-482
15. Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S, Tsuneyoshi M: Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 2004, 17:660-669
16. Nanni P, Nicoletti G, De Giovanni C, Croci S, Astolfi A, Landuzzi L, Di Carlo E, Iezzi M, Musiani P, Lollini PL: Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res 2003, 63:2728-2732
17. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK: Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 1990, 87:5863-5867
18. Wagner EF: AP-1-Introductory remarks. Oncogene 2001, 20:2334-2335
19. Shaulian E, Karin M: AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-2400
20. Eferl R, Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3:859-868
21. Hess J, Angel P, Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004, 117:5965-5973
22. van Dam H, Castellazzi M: Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 2001, 20:2453-2464
23. Thinakaran G, Bag J: Regulation of c-jun/AP-1 expression in rat L6 myoblasts. Biochem Cell Biol 1993, 71:197-204
24. Leibovitch MP, Leibovitch SA, Hillion J, Guillier M, Schmitz A, Harel J: Possible role of c-fos, c-N-ras and c-mos proto-oncogenes in muscular development. Exp Cell Res 1987, 170:80-92
25. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, Spiegelman BM: c-fos is required for malignant progression of skin tumors. Cell 1995, 82:721-732
26. Volm M, van Kaick G, Mattern J: Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases. Clin Exp Metastasis 1994, 12:329-334
27. Lassar AB, Thayer MJ, Overell RW, Weintraub H: Transformation by activated ras or fos prevents myogenesis by inhibiting expression of MyoD1. Cell 1989, 58:659-667
28. Tonin PN, Scrable H, Shimada H, Cavenee WK: Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res 1991, 51:5100-5106
29. Onisto M, Slongo ML, Gregnanin L, Gastaldi T, Carli M, Rosolen A: Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 2005, 27:791-798
30. Bohlander SK, Espinosa R, 3rd, Le Beau MM, Rowley JD, Diaz MO: A method for the rapid sequence-independent amplification of micro-dissected chromosomal material. Genomics 1992, 13:1322-1324
31. Breitling R, Armengaud P, Amtmann A, Herzyk P: Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004, 573:83-92
32. Yang YH, Dudoit S, Luu P, Speed TP. Normalization for cDNA microarray data. In microarrays: Optical Technologies and Informatics, vol 4266. Edited by ML Bittner, Y Chen, AN Dorsel, ER Dougherty. Berkeley, University of California, 2001, pp. 141-152
33. Hidestrand M, Richards-Malcolm S, Gurley CM, Nolen G, Grimes B, Waterstrat A, Zant GV, Peterson CA: Sca-1-expressing nonmyogenic cells contribute to fibrosis in aged skeletal muscle. J Gerontol A Biol Sci Med Sci 2008, 63:566-579
34. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW: Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 1997, 272:24735-24738
35. Vertino AM, Taylor-Jones JM, Longo KA, Bearden ED, Lane TF, McGehee RE, Jr., MacDougald OA, Peterson CA: Wnt10b deficiency promotes coexpression of myogenic and adipogenic programs in myoblasts. Mol Biol Cell 2005, 16:2039-2048
36. Miller JB: Myogenic programs of mouse muscle cell lines: expression of myosin heavy chain isoforms, MyoD1, and myogenin. J Cell Biol 1990, 111:1149-1159
37. Katoh M: WNT2 and human gastrointestinal cancer (review). Int J Mol Med 2003, 12:811-816
38. You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F, Jablons DM: An anti- Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 2004, 64:5385-5389
39. Caldas H, Holloway MP, Hall BM, Qualman SJ, Altura RA: Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. J Med Genet 2006, 43:119-128
40. Polesskaya A, Seale P, Rudnicki MA: Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. Cell 2003, 113:841-852
41. Pandur P, Maurus D, Kuhl M: Increasingly complex: new players enter the Wnt signaling network. Bioessays 2002, 24:881-884
42. Stambolic V, Ruel L, Woodgett JR: Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996, 6:1664-1668
43. Lee JL, Chang CJ, Chueh LL, Lin CT: Secreted frizzled related protein 2 (sFRP2) decreases susceptibility to UV-induced apoptosis in primary culture of canine mammary gland tumors by NF-kappaB activation or JNK suppression. Breast Cancer Res Treat 2006, 100:49-58
44. Tiffin N, Williams RD, Shipley J, Pritchard-Jones K: PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br J Cancer 2003, 89:327-332
45. Dagher R, Helman L: Rhabdomyosarcoma: an overview. Oncologist 1999, 4:34-44
46. Gerdes MJ, Myakishev M, Frost NA, Rishi V, Moitra J, Acharya A, Levy MR, Park SW, Glick A, Yuspa SH, Vinson C: Activator protein-1 activity regulates epithelial tumor cell identity. Cancer Res 2006, 66:7578-7588
47. Nusse R: Wnt signaling in disease and in development. Cell Res 2005, 15:28-32
48. Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA, Hsu FD, West RB, Nielsen TO: Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005, 18:68-74
49. Bouron-Dal Soglio D, Rougemont AL, Absi R, Giroux LM, Sanchez R, Barrette S, Fournet JC: Beta-catenin mutation does not seem to have an effect on the tumorigenesis of pediatric rhabdomyosarcomas. Pediatr Dev Pathol 2009, 12:371-373
50. Moon RT, Brown JD, Torres M: WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 1997, 13:157-162
51. Kawano Y, Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003, 116:2627-2634
52. Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, Dichgans J, Weller M: Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 2000, 19:4210-4220
53. Lu CM: DKK1 in multiple myeloma. N Engl J Med 2004, 350:1464-1466; author reply 1464-1466
54. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A, Gerstein R, Jurecic R, Jones SN: Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 2003, 4:349-360
55. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, Chan AT, Sung JJ, Tao Q: WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 2008, 14:55-61
56. Jonsson M, Dejmek J, Bendahl PO, Andersson T: Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 2002, 62:409-416
57. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939
58. Hamamori Y, Wu HY, Sartorelli V, Kedes L: The basic domain of myogenic basic helix-loop-helix (bHLH) proteins is the novel target for direct inhibition by another bHLH protein. Twist, Mol Cell Biol 1997, 17:6563-6573
59. Chiles MC, Parham DM, Qualman SJ, Teot LA, Bridge JA, Ullrich F, Barr FG, Meyer WH: Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group. Pediatr Dev Pathol 2004, 7:583-594
60. Shang YC, Zhang C, Wang SH, Xiong F, Zhao CP, Peng FN, Feng SW, Yu MJ, Li MS, Zhang YN: Activated beta-catenin induces myogenesis and inhibits adipogenesis in BM-derived mesenchymal stromal cells. Cytotherapy 2007, 9:667-681
61. Cossu G, Kelly R, Tajbakhsh S, Di Donna S, Vivarelli E, Buckingham M: Activation of different myogenic pathways: myf-5 is induced by the neural tube and MyoD by the dorsal ectoderm in mouse paraxial mesoderm. Development 1996, 122:429-437
62. Pan W, Jia Y, Huang T, Wang J, Tao D, Gan X, Li L: Beta-catenin relieves I-mfa-mediated suppression of LEF-1 in mammalian cells. J Cell Sci 2006, 119:4850-4856
63. Kim CH, Neiswender H, Baik EJ, Xiong WC, Mei L: Beta-catenin interacts with MyoD and regulates its transcription activity. Mol Cell Biol 2008, 28:2941-2951
64. Anakwe K, Robson L, Hadley J, Buxton P, Church V, Allen S, Hartmann C, Harfe B, Nohno T, Brown AM, Evans DJ, Francis-West P: Wnt signalling regulates myogenic differentiation in the developing avian wing. Development 2003, 130:3503-3514
65. Toualbi K, Guller MC, Mauriz JL, Labalette C, Buendia MA, Mauviel A, Bernuau D: Physical and functional cooperation between AP-1 and beta-catenin for the regulation of TCF-dependent genes. Oncogene 2007, 26:3492-3502